Funding for this research was provided by:
National Institute on Aging (1R44AG059489)
Alzheimer's Drug Discovery Foundation
Received: 19 January 2021
Accepted: 15 April 2021
First Online: 1 May 2021
: All study procedures were approved by Human Research Protection Boards/Committees at the respective institutions, namely Banner Alzheimer’s Institute, University of Florida, University of Wisconsin, and Washington University. Written informed consent was obtained from all participants.
: Not applicable.
: All authors are full time employees or advisors to C<sub>2</sub>N Diagnostics, receive equity or equity options, and contributed to the development of the plasma Aβ42, Aβ40, ApoE analytical platforms and the amyloid probability prediction models. DMH is as an inventor on a patent licensed by Washington University to C<sub>2</sub>N Diagnostics on the therapeutic use of anti-tau antibodies. C<sub>2</sub>N Diagnostics has licensed certain anti-tau antibodies to AbbVie for therapeutic development. DMH and RJB co-founded and are on the scientific advisory board of C<sub>2</sub>N Diagnostics. DMH is on the scientific advisory board of Denali and consults for Genentech, Merck, and Cajal Neuroscience. RJB receives personal fees from Amgen, AC Immune, Eisai, Hoffman-LaRoche, and Janssen Pharmaceuticals outside the submitted work. RJB receives income based on a blood plasma assay licensed by Washington University to C<sub>2</sub>N Diagnostics and has a patent (“Plasma Based Methods for Determining A-Beta Amyloidosis”) pending with Washington University.